Cellexus Appoints IUL as its Exclusive Distributor in Austria, Benelux, Germany, the Netherlands and Switzerland
News Jun 26, 2007
IUL distributes an extensive range of cell-based reagents and instruments to the biotechnology and biopharmaceutical industries, covering countries from Austria to the Netherlands. The Company’s headquarters are located in Germany, with a wholly owned subsidiary in the Netherlands.
Commenting on the agreement, Dr Kevin Auton, CEO of Cellexus Biosystems, said: “We were very clear from the outset that our strategy within the European Economic area required us to partner with organisations that had developed effective local sales channels. In choosing a partner for this region, we looked for a company that could provide our customers with the best service and support available - and this required a localised sales and support infrastructure. IUL is unusual in that the organisation operates throughout several of the countries that contain some of the highest densities of biopharmaceutical companies and research institutes within the European Economic area. This, coupled with expertise in microbiology and biotechnology, makes IUL an ideal partner in this region and we look forward to the added momentum that the company will bring to our expansion.”
Alexander Beljaars, Managing Director of IUL, commented: “Adding the CellMakerTM product range is an important strategic step for IUL to take. We have a wide range of products that we supply to our customers for microbiology and biotechnology and so the CellMaker bioreactors are a natural extension for us. We have built a very successful business as a distributor for other companies who manufacture products that are complementary to the CellMaker product range. We believe that our existing customer base will welcome the opportunity to invest in the CellMaker products, knowing that they have the local service and support that my organisation can provide.”
Researchers have found that two structurally similar compounds – deguelin and rotenone, naturally occurring pesticides produced by many plant species – interfered with melanoma cancer cells’ metabolism. Further testing with deguelin showed that it inhibited oxygen consumption in the cells’ mitochondria, effectively starving the cells of energy.READ MORE